| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/17/2011 | US20110039822 Heterocyclic janus kinase 3 inhibitors |
| 02/17/2011 | US20110039821 Fused Phenyl Amido Heterocyclic Compounds |
| 02/17/2011 | US20110039820 Lactam compounds useful as protein kinase inhibitors |
| 02/17/2011 | US20110039819 Substituted phenoxybenzamides |
| 02/17/2011 | US20110039818 Dosage regimen of an S1P receptor agonist |
| 02/17/2011 | US20110039817 4-aminopyrimidine derivatives as histamine h4 receptor antagonists |
| 02/17/2011 | US20110039816 Therapeutic substance, pharmaceutical composition, helicobacter pylori growth inhibitor and method for conducting anti-helicobacter therapy |
| 02/17/2011 | US20110039815 Macrocyclic metal complexes for their use as anticancer agents |
| 02/17/2011 | US20110039814 Lipid composition |
| 02/17/2011 | US20110039813 Method of utilization of combination of benzophenone derivative or salt thereof and immunosuppressing agent, and pharmaceutical composition comprising these components |
| 02/17/2011 | US20110039812 N-alkylcarbonyl-d-amino hydroxyalkyl ester compounds and their use |
| 02/17/2011 | US20110039811 Treating hyperglycemia with 25-hydroxyvitamin d3 |
| 02/17/2011 | US20110039810 Use of 25-hydroxy-vitamin d3 to affect human muscle physiology |
| 02/17/2011 | US20110039809 Combined use of 25-hydroxy-vitamin d3 and vitamin d3 for improving bone mineral density and for treating osteoporisis |
| 02/17/2011 | US20110039808 Multitarget Compounds Active at a PPAR and Cannabinoid Receptor |
| 02/17/2011 | US20110039807 Anti-parkinsonian compound acetylsalicylic acid maltol ester |
| 02/17/2011 | US20110039806 Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders |
| 02/17/2011 | US20110039805 Method for treating meibomian gland disease |
| 02/17/2011 | US20110039804 Composition of Risedronate and Vitamin D3 |
| 02/17/2011 | US20110039803 Solid forms of an anti-hiv phosphoindole compound |
| 02/17/2011 | US20110039802 Npy y5 antagonist |
| 02/17/2011 | US20110039801 Nk1 receptor antagonist composition |
| 02/17/2011 | US20110039800 Prolonged release bioadhesive therapeutic systems |
| 02/17/2011 | US20110039799 A1 adenosine receptor agonist polymorphs |
| 02/17/2011 | US20110039798 Substituted nucleoside derivatives with antiviral and antimicrobial properties |
| 02/17/2011 | US20110039797 Oligomer Conjugates of Heteropentacyclic Nucleosides |
| 02/17/2011 | US20110039796 Natural Composition for Anti-Angiogenesis and Anti-Obesity |
| 02/17/2011 | US20110039795 2'-o,3'-n-bridged macrolides |
| 02/17/2011 | US20110039794 Long Acting Injectable Formulations |
| 02/17/2011 | US20110039793 Application of ginsenoside Rb1 in preparing medicaments for treating dilated cardiomyopathy |
| 02/17/2011 | US20110039789 Use of Huntingtin Protein for the Diagnosis and the Treatment of Cancer |
| 02/17/2011 | US20110039788 Compositions, methods and kits for detecting and treating cancer |
| 02/17/2011 | US20110039784 Composition for treatment of erectile dysfunction |
| 02/17/2011 | US20110039772 Novel uses of vegfxxxb |
| 02/17/2011 | US20110039764 Therapeutic composition for bone infectious disease |
| 02/17/2011 | US20110039759 Use of Secretin-Receptor Ligands in Treatment of Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD) |
| 02/17/2011 | US20110039714 Probes, Systems, and Methods for Drug Discovery |
| 02/17/2011 | US20110038968 Topical Composition with Skin Lightening Effect |
| 02/17/2011 | US20110038965 Topical formulation and uses thereof |
| 02/17/2011 | US20110038958 Use of cannabinoids in combination with an anti-psychotic medicament |
| 02/17/2011 | US20110038957 Novel nutraceutical compositions containing stevia extract or stevia extract constituents and uses thereof |
| 02/17/2011 | US20110038955 Prevention of gastric ulcer by carbon monoxide |
| 02/17/2011 | US20110038953 Strontium compound for treatment of sub-dermal soft tissue pain |
| 02/17/2011 | US20110038952 Gambogic acid glycoside derivatives and analogs, their preparation methods and applications |
| 02/17/2011 | US20110038950 Enhanced erythropoiesis and iron metabolism |
| 02/17/2011 | US20110038946 Release of antibiotic from injectable, biodegradable polyurethane scaffolds for enhanced bone fracture healing |
| 02/17/2011 | US20110038943 Milkweed seed oil administered to animals |
| 02/17/2011 | US20110038941 Lipid Nanoparticle Compositions and Methods of Making and Using the Same |
| 02/17/2011 | US20110038940 Pulverulent composition and a process for preparing the same |
| 02/17/2011 | US20110038938 Compositions for tissue augmentation |
| 02/17/2011 | US20110038937 Methods for delivering siRNA via Ionthophoresis |
| 02/17/2011 | US20110038936 System and method for electrospun drug loaded biodegradable chemotherapy applications |
| 02/17/2011 | US20110038934 Pharmaceutical composition with atorvastatin active ingredient |
| 02/17/2011 | US20110038933 Stable benzimidazole formulation |
| 02/17/2011 | US20110038932 Methods and materials for treating conditions associated with metabolic disorders |
| 02/17/2011 | US20110038931 Composite preparation |
| 02/17/2011 | US20110038930 Hot-melt extruded pharmaceutical dosage form |
| 02/17/2011 | US20110038928 Orally disintegrating tablets of zolmitriptan |
| 02/17/2011 | US20110038927 Controlled release hydrocodone formulations |
| 02/17/2011 | US20110038926 Method of producing a cationic liposomal preparation comprising a lipophilic compound |
| 02/17/2011 | US20110038925 Intravenous formulations of neurokinin-1 antagonists |
| 02/17/2011 | US20110038923 Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression |
| 02/17/2011 | US20110038922 Compounds for treating or preventing amine oxidase related diseases or disorders |
| 02/17/2011 | US20110038921 Methods and compositions for temporal release of agents from a biodegradable scaffold |
| 02/17/2011 | US20110038920 Wound healing compositions and treatments |
| 02/17/2011 | US20110038919 Textile materials with adhesive and methods for use thereof |
| 02/17/2011 | US20110038918 Composition For Transdermal Delivery of Fentanyl |
| 02/17/2011 | US20110038916 Sanitizers |
| 02/17/2011 | US20110038908 Formulations and methods employing anhydrous disinfectant |
| 02/17/2011 | US20110038899 Pharmaceutical Solutions and Method for Solublilizing Therapeutic Agents |
| 02/17/2011 | US20110038898 Dissolution properties of drug products containing olmesartan medoxomil |
| 02/17/2011 | US20110038897 Oral controlled release formulations |
| 02/17/2011 | US20110038876 Heterocyclic compounds and use thereof as erk inhibitors |
| 02/17/2011 | US20110038873 Means and methods for treating or preventing brain tumors based on the nuclear receptor tailless (tlx) |
| 02/17/2011 | US20110038862 Method and kit for the detection of genes associated with pik3ca mutation and involved in pi3k/akt pathway activation in the er-postitive and her2-positive subtypes with clinical implications |
| 02/17/2011 | US20110038860 Methods for inhibition of polyclonal b cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking cd1-mediated interactions |
| 02/17/2011 | US20110038858 Methods of treating hematologic cancers using pnp inhibitors such as forodesine in combination with alkylating agents or anti-cd20 agents |
| 02/17/2011 | US20110038857 Novel aza-bicyclic compounds and their use as stimulators of soluble guanylate cyclase |
| 02/17/2011 | US20110038856 Methods of treating neoplastic, autoimmune and inflammatory diseases |
| 02/17/2011 | US20110038853 Use of Kif13A and AP-1 Inhibitors for Inhibiting Melanogenesis |
| 02/17/2011 | US20110038852 Antivirals that target transporters, carriers, and ion channels |
| 02/17/2011 | US20110038851 Treatment of synucleinopathies |
| 02/17/2011 | US20110038849 Inhibitory polynucleotide compositions and methods for treating cancer |
| 02/17/2011 | US20110038848 Dietary supplement compositions for cardiovascular health |
| 02/17/2011 | US20110038843 Tumor Growth Inhibition Via Conditioning of Tumor Microenvironment |
| 02/17/2011 | US20110038835 Anilides and analogs as rho kinase inhibitors |
| 02/17/2011 | US20110038833 Modified fluorinated nucleoside analogues |
| 02/17/2011 | US20110038832 Method for treatment of macular degeneration using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| 02/17/2011 | US20110038829 Methods and materials for treating diarrhea |
| 02/17/2011 | US20110038828 Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same |
| 02/17/2011 | US20110038827 Elevation of the plasma hdl-cholesterol level |
| 02/17/2011 | US20110038809 Growth control of oral and superficial microorganisms using gallium compounds |
| 02/17/2011 | US20110038807 Compositions and methods for treating bipolar disorder |
| 02/17/2011 | US20110038806 Medicaments for inhalation comprising an anticholinergic and a steroid |
| 02/17/2011 | US20110038805 Compounds comprising paramagnetic chelates arranged around a central core and their use in magneto resonance imaging and spectroscopy |
| 02/17/2011 | US20110038800 Method for the treatment or prophylaxis of lymphagioleiomymatosis (lam) and animal model for use in lam research |
| 02/17/2011 | US20110038793 Microsphere comprising an organic lanthanide metal complex |
| 02/17/2011 | US20110038792 Induction of thyroid iodide-handling gene expression in human cancers |
| 02/17/2011 | US20110038791 Methods for inhibiting six1 and eya proteins |
| 02/17/2011 | CA2808582A1 Imidamide sphingosine kinase inhibitors |